• PD98059 MEK Inhibitor: Workflows & Applications

  2026-09-24

  Use PD98059 to test whether MEK–ERK signaling contributes to oxidative injury, cell-cycle changes, or apoptosis—not simply to label a pathway as active. This practical guide connects a cyclophosphamide liver-injury study to reproducible assay design, with dose-planning, controls, and troubleshooting for cell-based experiments.

• Cyclo (-RGDfC) in 96-Well Integrin Assays

  2026-09-24

  Combine the αvβ3-binding cyclic peptide c(RGDfC) with 96-well hydrogel workflows to test integrin-dependent cell behavior under controlled, reproducible conditions. The approach pairs a soluble ligand competition assay with flexible light-based substrate fabrication—without assuming the peptide itself is light-activated or validated in the printer study.

• Ceftolozane Sulfate: Assay and PK/PD Workflows

  2026-09-24

  Build a reproducible Ceftolozane sulfate workflow around broth microdilution, resistant-isolate stratification, and exposure-to-MIC analysis. The guide distinguishes what cefiderocol surveillance data can inform from what must be tested directly for Ceftolozane.

• ABT-737 BCL-2 Protein Inhibitor Workflow

  2026-09-23

  Use ABT-737 as a mechanistically defined benchmark for mitochondrial apoptosis, with practical workflows spanning lymphoma, multiple myeloma, SCLC, and AML models. Its value is amplified by pairing BCL-2 family readouts with RNA Pol II degradation-response assays that distinguish active death signaling from passive transcriptional collapse.

• ABT-263 (Navitoclax): Apoptosis Research Guide

  2026-09-22

  ABT-263, also called Navitoclax, is an orally bioavailable BCL-2-family inhibitor that engages BCL-2, BCL-XL, and BCL-W to promote mitochondrial apoptosis. This guide connects its binding profile, cancer biology applications, pediatric acute lymphoblastic leukemia evidence, formulation limits, and apoptosis assay design.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-22

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It produces blunt-ended PCR products for compatible cloning and sequencing workflows, but it is not the correct choice when 3′-A overhangs or preformed sticky ends are required.

• N1-Methylpseudouridine for mRNA Assay Design

  2026-09-21

  Learn how N1-Methylpseudouridine can improve mRNA translation enhancement while helping researchers separate delivery effects from innate immune and stress-response artifacts. This workflow also shows how modified mRNA assays can complement CRISPR-based studies of PCMT1, anoikis resistance, and ovarian cancer metastasis.

• Anlotinib in Desmoplastic Small Round Cell Tumor

  2026-09-21

  This case report and literature review describes the first reported clinical use of anlotinib in metastatic intra-abdominal desmoplastic small round cell tumor, with radiographic reduction of metastatic lymph nodes and manageable toxicity. Its main value is hypothesis generation: the report supports further investigation of multi-target receptor tyrosine kinase inhibition in a tumor with few standardized treatment options, while not establishing efficacy in a controlled cohort.

• BRCA1/BARD1, pre-rRNA, and Homologous Recombination

  2026-09-20

  Wu and colleagues identify pre-ribosomal RNA as a functional partner that recruits the BRCA1/BARD1 complex to DNA double-strand breaks and supports homologous recombination. Their results connect BRCT-domain recognition, RNA-driven phase separation, cancer-associated mutations, and PARP inhibitor sensitivity in a unified mechanism of genome maintenance.

• Cediranib (AZD2171): Beyond the Viability Readout

  2026-09-19

  Cediranib (AZD2171) is a potent VEGFR-pathway probe for studying angiogenesis, signaling, and tumor biology. This guide shows how to interpret pathway suppression, growth inhibition, and cell death as distinct but connected experimental outcomes.

• Azithromycin Workflows for Infection Research

  2026-09-19

  Build more reproducible infection, resistance, and impurity-control experiments with Azithromycin, a macrolide antibiotic that connects ribosomal mechanism to practical assay design. This guide combines culture screening, quantitative TLC, host-cell readouts, and carefully bounded animal-model translation.

• Shh–Fgf Signaling in Guinea Pig Penile Development

  2026-09-18

  Wang and Zheng used comparative developmental analysis to explain why guinea pigs form a fully open urethral groove whereas mice form the penile urethra primarily by urethral plate canalization. Their expression mapping and ex vivo perturbation experiments identify differential Shh, Fgf10, and Fgfr2 activity as a major mechanistic factor linking urethral groove formation with the timing of preputial development.

• ABT-737: BCL-2 Protein Inhibitor Workflows

  2026-09-17

  ABT-737 provides a practical way to test mitochondrial apoptosis dependence across lymphoma, multiple myeloma, small-cell lung cancer, and AML models. This workflow connects concentration–response experiments with endogenous BAX/BAK imaging, helping distinguish genuine pathway activation from assay or overexpression artifacts.

• ABT-263 (Navitoclax) Apoptosis Workflows

  2026-09-17

  ABT-263 (Navitoclax) converts Bcl-2 family dependence into a practical experimental variable for apoptosis, senescence, and cancer biology studies. This guide shows how to pair dose-response testing with real-time imaging, mitochondrial priming, and caspase readouts to distinguish true senolytic sensitivity from nonspecific toxicity.

• ABT-263 (Navitoclax) Apoptosis Workflow

  2026-09-16

  ABT-263 (Navitoclax) converts Bcl-2 family dependence into a measurable experimental variable for apoptosis, mitochondrial priming, and cancer biology studies. This guide connects dose-response design with orthogonal cell-death readouts and the emerging insight that Pol II degradation can activate death independently of transcriptional loss.

8064 records 1/538 page Next 12345 下5页 Last page